Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

Nature Medicine 2026 Open access

Read full text
Authors: Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, Heiko Becker, Annalen Bleckmann, Farastuk Bozorgmehr, Manik Chatterjee, Stefanie Groepper, Mathias Haenel, Judith S. Hecker, Max‐Felix Häring, Daniel Heudobler
+15 more Norbert Hilf, Martin Hofmann, Meike Hutt, Andrea Mayer-Mokler, Sarah Missel, Manuel Ruh, Heiko Schuster, Ольга Веремчук, Moritz Kleemiss, Stefan Tobias Knop, Simon A. Laban, Martin Sebastian, Silvia Spoerl, Cedrik Michael Britten, Carsten Reinhardt
DOI: 10.1038/s41591-026-04519-y
Cited by: 1

Abstract

In the version of the article initially published, in the “Phase 1a dose escalation” column in Fig. 2, the fifth dose was listed as “0.054 mg” but should have been “0.54 mg”. This correction has been made to the HTML and PDF versions of the article.

Fields of Study & Subjects

CAR-T cell therapy research Immunotherapy and Immune Responses Monoclonal and Polyclonal Antibodies Research

Publication details

Journal / source
Nature Medicine
Publisher
Springer Science and Business Media LLC
Volume
32
Issue
8
Pages
3094–3094
Publication date
19 June 2026
Language
EN